Blood test could help doctors switch cancer drugs faster

NCT ID NCT05770531

Recruiting now Disease control Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic triple-negative breast cancer. The study compares standard care with a strategy where ctDNA results guide an earlier switch to the drug sacituzumab govitecan. About 160 participants will be enrolled to see if this approach improves how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab govitecan
What this could lead to: If successful, this approach could help doctors detect when chemotherapy is failing earlier and switch to a more effective treatment, potentially improving survival and quality of life for patients with metastatic triple-negative breast cancer.
What could go wrong: This is a phase 2 trial with only 160 participants, so results may not apply to all patients. The ctDNA test is still investigational, and there is no guarantee it will lead to better outcomes or that sacituzumab govitecan will work better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HER2-NEGATIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Her2-receptor negative breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HER2-NEGATIVE BREAST CARCINOMA METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Locations

Vanderbilt University/Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.